what is the mechanism of action of glp-1 agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Weight Loss and Maintenance Related

Description

But the exact mechanism by which this therapeutic effect sometimes becomes a pathological one, where delayed emptying crosses the line into permanent gastroparesis, remains unclear

References Mller TD, Finan B, Bloom SR, DAlessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH

[159] As of February 2026, Novo Nordisk has a market capitalization of $220.42 billion

The results showed high heterogeneity of weight loss from the baseline weight between individuals even at the highest dose of tirzepatide 38.4 to 9.0 kg and mean 22.1 kg